Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Larregina AT
Scientific Tracks Abstracts: JCEDR
Skin inflammatory diseases are regulated by a synchronized interaction of the immune and nervous systems that takes place during the process known as neuro inflammation. Contact hypersensitivity, (CHS) and atopic dermatitis (AD) are prototype recurrent skin inflammatory diseases initiated and sustained by type-1 and type-2 biased T cell responses, respectively. The activation and bias of CD4+ and CD8+ effectors/memory T cells is initiated by cutaneous immune stimulatory dendrite cells (DC). Studies from our laboratory and others, focused on skin immune-regulation, have demonstrated that stimulation and bias of cutaneous DCs depend on the presence of appropriate biasing pro inflammatory signalling during the interaction between the hapten/allergen and the DC. This inflammatory microenvironment is controlled, at least in part, by pro-inflammatory neuro peptides secreted locally in the skin by nerve terminals. In fact, delta-sensory fibers of the skin make direct contact w ith cutaneous DCs and mast cells, which are targets of the pro- inflammatory neuro peptides Substance-P (SP) and Calcitonin Gene Related Peptide (CGRP). SP favors cellular immunity by promoting the activation, proliferation and survival CD4+ T helper-1(Th1) and CD8+ T cytotoxic cells (Tc1), whereas CGRP promotes type 2 responses and humoral immunity. Here, I will discuss the role and mechanisms employed by these two cutaneous pro inflammatory neuro peptides regarding the regulation of skin chronic inflammatory diseases.
Dr. Adriana T Larregina, M.D.; Ph.D. and Pathologist completed her medical and doctorate degrees at Buenos Aires University, Ar gentina. Her PhD dissertation focused on the study of activation of human skin dendritic cells. After fi nalizing her PhD degree she completed a postdoctoral position at the Victoria University of Manchester in the fi eld of genetic modi fi cation of cells that she intended to apply for her future scienti fi c career analyzing the possibility to develop ef fi cient genetic immunizations. To achieve this goal Dr Larregina accepted a position of Research Instructor at the Department of Dermatology of the University of Pittsburgh. She was soon promoted to Assistant Professor and Associate Professor (Tenure) o f Dermatology, Immunology and the McGowan Institute for Regenerative Medicine at the School of Medicine of the University of Pittsburgh (PA).